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The hypercoagulable syndromes remind one of
the numerous poisonous snakes that sprang from the
blood of Medusa (the mortal daughter of the sea
god Phorcus) after her head was cut off by the sword
of Perseus. Although the hypercoagulable syn-
dromes are not snakes, they are numerous and
potentially dangerous, and new disorders spring
forth at frequent intervals.
Most investigators would agree that thrombosis
is the cause of, or is related to the cause of, most
deaths. Bick and Kaplan1 have estimated that almost
two million individuals die in the United States each
year from “an arterial or venous thrombosis or the
consequences thereof” and that more than “…50%
of all patients harbor a congenital or acquired blood
coagulation protein or platelet defect that caused the
thrombotic event.” Stassen and Nystrom2 suggested
in 1997 that the “…annual hospitalizations due to
all thrombotic disease exceeded 5,100,000 in the
United States…” and that the annual costs for these
disorders were “…about $13 billion.”
Physicians frequently encounter patients who
have venous thromboses without obvious risk fac-
tors, who have recurrent venous thromboses devel-
op in spite of the usual methods for preventing the
recurrence, or who have venous thromboses develop
in unusual locations. The vascular surgeon also occa-
sionally encounters patients with unexplained arteri-
al thromboses or with unexplained arterial recon-
structive failures. Many of these patients will have
congenital or acquired hypercoagulable disorders
that sensitize them to prothrombotic conditions that
are tolerated by most individuals.
We review the pathophysiology and management
of the hypercoagulable disorders that are most likely
to be of concern to vascular surgeons. If a disorder
can be recognized, then the appropriate manage-
ment may control the thrombotic tendency and pre-
vent future thromboses.
ACQUIRED HYPERCOAGULABLE DISOR-
DERS (TABLE I)
Technical failures (badly diseased vessels, inade-
quate inflow or outflow, kinked or twisted grafts,
etc) remain the most common cause of the early
arterial reconstructive failures encountered by vascu-
lar surgeons and can be reduced with the appropri-
ate preoperative planning and careful attention to
operative detail. Most of the operative procedures
that are performed by vascular surgeons predispose
the patient, at least at the site of the operative pro-
cedure, to thrombosis. If there is inadequate antico-
agulation therapy during the time the blood flow is
diverted from the operative area, thromboses will
form proximal and distal to the clamps and subse-
quently in the operative area. Procedures, such as
endarterectomy, angioplasty, and thrombectomy
catheter placement, remove or damage the intima
and expose deep layers of the arterial wall, which
activate platelets and the coagulation mechanism.
Synthetic grafts are not protected by endothelial
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cells and are at risk for thrombosis. If adequate
blood flow is restored to an operative site and if the
blood was hypocoagulable during the time of cessa-
tion of flow, then the vascular surgical procedure is
almost always successful. Small diameter prosthetic
grafts or vascular reconstructions associated with low
flow conditions are prone to thrombosis. This sec-
tion will review some of the disorders that may
adversely affect arterial vascular reconstructions or
induce venous or arterial thromboses (Table I).
SMOKING
Smoking contributes to arterial thrombosis and
atherogenesis through a variety of mechanisms.
Nicotine and carbon monoxide appear to be the most
harmful constituents. The incidence rates of critical
limb ischemia (16% vs 0%) and myocardial infarction
(53% vs 11%) are much greater in smokers than in
nonsmokers, when followed for as long as 10 years.3
Furthermore, cigarette smoking has an adverse effect
on arterial bypass grafts, with twice as many grafts
being patent in nonsmokers than in smokers at the
end of 2 years.4 The patients who continue to smoke
after vascular reconstruction have a high risk of recur-
ring ischemia and subsequent loss of limb or organ.5
Nicotine results in endothelial damage and
desquamation, which leads to platelet deposition, the
release of platelet-derived growth factor, and platelet-
mediated intimal and medial hyperplasia. Carbon
monoxide increases the permeability of the endothe-
lium, which results in an increased deposition of lipids
(nicotine increases the levels of circulating free fatty
acids) in the media, leading to the production of
atheromas. Smoking reduces the synthesis of prosta-
cyclin, a potent vasodilator and inhibitor of platelet
aggregation. Smoking has adverse effects on blood
viscosity (increased), coagulation (increased), and
platelet activation (increased).6,7 All patients, especial-
ly those with arterial occlusive disease, should be
encouraged to refrain from, or discontinue, smoking.
HEPARIN-INDUCED 
THROMBOCYTOPENIA
Heparin-induced thrombocytopenia occurs in
2% to 3% of the patients who undergo heparin ther-
apy. Of the patients who underwent vascular recon-
struction, 21% had heparin-associated antiplatelet
antibodies develop, and 18.2% of these patients had
heparin-induced thromboses develop.8
When patients who have heparin-associated
antiplatelet antibodies undergo heparin therapy,
their activated platelets induce platelet aggregation
and thrombosis and rarely hemorrhage. The anti-
bodies also activate endothelial cells that contribute
to the production of thromboses. The development
of the antibodies is independent of patient age or
sex, the route of the administration of heparin, or
the amount of heparin received. All forms of
heparin, including low–molecular weight heparin,
can result in the production of these antibodies. The
antibodies usually occur in patients between the 5th
to the 8th day during the first exposure to heparin
and may recur during the first day of a patient’s reex-
posure to heparin. The clinical manifestations
include: a falling platelet count; an increasing resis-
tance to anticoagulation therapy with heparin; or
new thrombotic, rarely hemorrhagic, events. The
paradox is that heparin anticoagulation therapy
places these patients at risk for a heparin-induced
thrombosis.
When the vascular surgeon completes a technical-
ly successful procedure, with normal postoperative
angiographic or ultrasound scan study results, only to
have a thrombosis occur in the operating room or in
the recovery room, he should suspect heparin-
induced thrombocytopenia with thrombosis. When
this occurs, one must inhibit platelet function, usual-
ly with aspirin or dextran, and discontinue the use of
all forms of heparin. The patient’s plasma should be
tested for the presence of the heparin-associated
antiplatelet antibodies. If the antibodies are present,
the patient should be warned not to accept any form
of heparin therapy in the future without testing for
the specific type of heparin to which that patient is to
be exposed. The heparin-associated antiplatelet anti-
bodies, like drug-induced antibodies, remit in a few
Table I. Causes of acquired hypercoagulability
Causes
Smoking*
Heparin-induced thrombocytopenia*
Warfarin*
Antiphospholipid syndrome*
Pregnancy*
Oral contraceptives*
Diabetes mellitus
Hyperlipidemia
Polycythemia vera
Hyperfibrinogenemia
Nephrotic syndrome
Vasculitis
Malignant disease
Surgery
Thrombocythemia
Homocystinemia
*Disorders that may adversely affect arterial vascular reconstruc-
tions or induce venous or arterial thromboses.
weeks to months. However, we have found that the
heparin-associated antiplatelet antibodies can persist
as long as 13 years.
The heparin-induced thrombocytopenia syn-
drome is one of the more common and potentially
devastating hypercoagulable disorders encountered
in patients who undergo vascular surgery. The man-
agement of heparin-induced thrombocytopenia syn-
drome includes the avoidance of all forms of heparin
to which the patient is sensitized. We routinely test
the patient’s antibodies against beef heparin, pork
heparin, enoxaparin, and fragmin. The rare patient
may react with all four heparins, but most patients
do not. If a heparin to which a patient does not cross
react is found, we offer a brief exposure to that type
of heparin, with retesting in a few days to determine
whether the patient has now developed antibodies to
the “new” type of heparin. We have found positive
reactions with enoxaparin in 34% and a positive reac-
tion with fragmin in 25.5% of our patients with
heparin-induced thrombocytopenia.9,10 For the rare
patient who is unable to undergo any form of
heparin anticoagulation therapy, the recent Food and
Drug Administration–approved thrombin inhibitor
lepirudin (Refludan, Hoechst Marion Roussel,
Kansas City, Mo) is a satisfactory anticoagulant.
WARFARIN-INDUCED THROMBOSIS
The most serious nonhemorrhagic complication
of oral anticoagulation therapy is warfarin-induced
skin necrosis, which is manifested by thrombosis and
hemorrhage of venules and capillaries within the
subcutaneous fat and the overlying skin. The skin
necrosis occurs most typically in the subcutaneous
fat of the breasts, thighs, buttocks, and legs.
Warfarin inhibits the action of vitamin K in the liver,
which leads to reductions of functional factors II,
VII, IX, and X and proteins C and S. Protein C and
factor VII have short half lives of approximately 6
hours and are quickly reduced early during warfarin
therapy. The other vitamin K–dependent factors
have significantly longer half lives, and therapeutic
anticoagulation treatment with warfarin requires 3
to 4 days. However, the induced deficiency of pro-
tein C (an anticoagulant that inactivates activated
factors Va and VIIIa) induces a hypercoagulable
state during the first 2 to 3 days of warfarin therapy.
It is recommended that the patients with risk factors
for intravascular thrombosis, especially those
patients with protein C and S deficiencies, or the
patients who have had previous episodes of warfarin-
induced skin necrosis should be protected with
heparin for the first 2 to 4 days of anticoagulation
therapy with warfarin. The low–molecular weight
heparins allow one to “protect” the patients much
more easily than has been possible in the past.
ANTIPHOSPHOLIPID SYNDROME
The antiphospholipid syndrome is another of the
commonly acquired causes of hypercoagulability. It
occurs in 1% to 5% of the population and increases
with age (50% of patients older than 80 years have
antiphospholipid antibodies.)11 The antiphospho-
lipid syndrome occurs in patients with lupus antico-
agulants or anticardiolipin antibodies. The patients
with these disorders develop antibodies to protein-
phospholipid complexes. The antibodies are direct-
ed against neoepitopes of the plasma proteins, espe-
cially those of β 2 glycoprotein I and prothrombin,
which are formed when the substances bind to anti-
anionic-phospholipids. Antibodies have also been
identified that react to other phospholipid complex-
es with protein C or protein S, factors XI and XII,
and high–molecular weight kininogen. The antibod-
ies also react with phospholipids on platelets and
endothelial cells. The endothelial reactions block the
antithrombin inactivation of thrombin and the
thrombomodulin activation of protein C.
Recurrent venous thrombosis is a manifestation of
the antiphospholipid syndrome.12 The incidence rate
of thrombotic complications after vascular surgical
procedures in patients with lupus anticoagulants has
been reported to be as high as 50%.13 The patients
with systemic lupus erythematosus, malignant disease,
and peripheral vascular occlusive disease, who have cir-
culating lupus anticoagulants or anticardiolipin anti-
bodies, have a high incidence of pulmonary embolism,
vena cava thrombosis, myocardial infarction, acute
arterial occlusion, and abortion.14 Arterial thromboses
are known to occur in the brain, eye, and heart, and in
the periphery. Another clinical manifestation of the
antiphospholipid syndrome is that of recurrent, usual-
ly mid-pregnancy, abortion. Thrombocytopenia is a
common occurrence.
The diagnosis of the antiphospholipid syndrome
includes testing for the lupus anticoagulant, which is
manifested with prolongation of clotting assays
(activated partial thromboplastin time, prothrombin
time, Russel’s viper venom time). These tests do not
correct with a 1:1 mixture of healthy plasma with
the patient’s plasma. The anticardiolipin antibodies
are detected with enzyme-linked immunosorbent
assay. Patients should undergo both tests.
The management of the antiphospholipid syn-
drome includes the elimination of risk factors in those
patients with known antibodies (eg, warn against preg-
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nancies, avoid oral contraceptives, avoid major trau-
ma). Those patients with recurrent venous thromboses
should be treated immediately with heparin or uroki-
nase and then later with the life-long administration of
warfarin. An international normalized ratio (INR) of
2.0 to 3.0 usually provides adequate protection.
However, a few patients require an INR of 3.0 to 4.0.
Patients with anticardiolipin antibodies and previous
deep venous thrombosis or abortion who become
pregnant undergo treatment during the pregnancy
with heparin and after the pregnancy with warfarin.
Warfarin therapy should be continued as long as the
antibodies or anticoagulant persist.
PREGNANCY
Women who are pregnant (particularly during
the puerperium) and women who use exogenous
estrogens have increased risks for thromboem-
bolism. The hypercoagulable state of pregnancy has
been described as a state of disseminated intervascu-
lar coagulation.15 During pregnancy, there is an
increase in coagulation factors I, VII, VIII, IX, X,
XI, and XII, an increase in platelet count, a decrease
in protein S, and a decrease of antithrombin. In
addition, the fibrinolytic system may be inhibited by
increased levels of plasminogen-activated inhibitor-1
and inhibitor-2, which are produced by the placen-
ta. These events contribute to an increased (five-
fold) risk of venous thrombosis during pregnancy,
which is compounded by the venous stasis produced
by the pregnant uterus compressing the veins drain-
ing the lower extremities. The risk of thrombosis is
higher in the antepartum period (by 20 fold) than in
the anti-partum period.16 The coagulation and fibri-
nolytic systems return to normal approximately 2
months after delivery.
Recent studies have indicated that the hyperco-
agulable potential of the pregnant state is signifi-
cantly amplified by inherited conditions of hyperco-
agulability (eg, antithrombin and protein C defi-
ciencies and the presence of the Leiden mutation).17
Kupferminc et al18 have demonstrated that “Women
with serious obstetrical complications have an
increased incidence of mutations predisposing them
to thrombosis and other inherited and acquired
forms of thrombophilia.” They demonstrated that
52% of women with severe thrombotic obstetrical
complications had congenital hypercoagulable syn-
dromes including: factor V Leiden mutation; the
prothrombin gene variant (20210A); protein C,
protein S, antithrombin deficiencies; and the pres-
ence of anticardiolipin antibodies. The “complicated
group” also had increased hyperhomocystinemia
(22% for the patients with complications as com-
pared with 8% of the control group). The authors
recommended that “…women with severe compli-
cated pregnancies should be tested for markers of
thrombophilia….”
Heparin is the preferred anticoagulant therapy for
pregnant women because it does not cross the pla-
centa. Warfarin crosses the placenta, is teratogenic, is
associated with fetal hemorrhage, and should not be
offered to the pregnant patient. In addition, the preg-
nant woman should be encouraged to avoid the posi-
tion of stasis and to use elastic support for the lower
extremities. It has been suggested that the patients
with congenital thrombophilia undergo prophylactic
heparin therapy (ie, subcutaneous standard heparin
therapy or low–molecular weight heparin therapy)
throughout their pregnancy.
Estrogens have been associated with a two-fold
to 11-fold increase in the incidence of venous
thrombosis in women.19,20 There is also an
increased risk for coronary and cerebral arterial
thromboses in women who use oral contraceptives.
The thrombosis rate increases as the estrogen dose
increases. Estrogens are associated with falls in
antithrombin and protein S activities and increases in
the levels of activated factors VII and X.21,22 Women
who use the third generation “pills,” which contain
newer progestin derivatives, have a higher risk for
deep vein thrombosis (2.6-fold increase as compared
with the first generation contraceptives, and a 9.1-
fold increase as compared with nonusers).23 The
estrogens have also been associated with decreased
levels of thrombomodulin, which leads to a reduc-
tion in the activity of protein C.21 An acquired acti-
vated protein C resistance (APC-R), or the presence
of factor V Leiden mutation, plus third generation
contraceptive use places the patient at a markedly
increased risk, as much as a 49.8-fold increase, for
thrombosis as compared with control patients.24
The vascular surgeon must be aware that the patient
who uses an estrogen contraceptive is at an increased
risk for venous and arterial thromboembolism and
should be especially wary of the patient who uses a
third generation contraceptive.
A woman in whom a venous thrombosis devel-
ops while undergoing estrogen therapy should be
treated like any patient with acute venous thrombo-
sis and should be advised to use other forms of birth
control. If there is family history of venous throm-
bosis, or if there is recurrent venous thrombosis,
then a search should be made for congenital hyper-
coagulable disorder (ie, APC-R, the Leiden muta-
tion, prothrombin variant, or reductions in protein
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C, protein S, or antithrombin.) If the patient has
congenital hypercoagulability and recurrent throm-
bosis, she should undergo long-term warfarin anti-
coagulation therapy with the prothrombin at an
INR of 2.0 to 3.0.
OTHER ACQUIRED HYPERCOAGULABLE
DISORDERS
Many clinical disorders predispose patients to
thrombosis by activating the coagulation system,
inhibiting the fibrinolytic system, or initiating
platelet activation. Soft tissue trauma, thermal
injuries, and operative dissection predispose one to
thrombosis through the activation of the extrinsic
pathway of coagulation with the release of tissue fac-
tor. Sepsis predisposes a patient to thrombosis with
the increased production and expression of tissue
factor by endothelial cells, macrophages, and neu-
trophils; with the decrease of antithrombin, protein
C, and protein S, and thrombomodulin activity
(uninhibited thrombogenesis); and with the increase
in production of plasminogen activator inhibitor-1
(suppressed fibrinolytic activity).25-27
Malignant diseases are associated with the
increased incidence of venous thrombosis. Many
malignant diseases cause the secretion of tissue
thromboplastin, and others are known to cause the
release of proteases capable of activating factor X.
Some patients with malignant disease have increased
concentrations of factors V, VIII, IX, and X.
Patients with hyperlipidemia, myeloproliferative
diseases, diabetes mellitus, and thrombotic thrombo-
cytopenia are all predisposed to thrombosis through
the effects on platelets. Hyperlipidemia causes the acti-
vation of platelets, with the increase of thromboxane
A2 and the decrease of platelet response to prostacy-
clin.28,29
CONGENTIAL HYPERCOAGULABLE SYN-
DROMES (TABLE II)
The congenital defects of coagulation/anticoagu-
lation proteins may result in an imbalance in hemo-
stasis, which leads to an increased thrombotic risk for
the patient. All of the congenital hypercoagulable
disorders increase the risk for venous thrombosis, but
several also contribute to increased arterial throm-
boses. Some patients who are thrombophilic have
multiple genetic disorders (eg, the frequent associa-
tion of factor V Leiden mutation with deficiencies of
antithrombin and proteins C and S). Table II lists the
congential hypercoagulable disorders: the more
prevalent ones are subsequently discussed.
ANTITHROMBIN DEFICIENCY
Antithrombin, the major plasma inhibitor of
thrombin, also inhibits factors IXa, Xa, XIa, and
XIIa. The antithrombin deficiency, described in
1965 by Egeberg30 in a Norwegian family with
repeated thrombotic episodes, has a prevalence of
1:5000. Patients with low levels of antithrombin are
at risk for venous thromboses, especially lower
extremity and mesenteric, but are also at increased
risk for arterial thromboses. The risk of thrombosis
increases as the functional antithrombin activity
decreases to less than 80% of the normal level, with
the highest risk occurring when antithrombin levels
are less than 60%.31 The level of antithrombin in
heterozygotes usually is 40% to 70% of the normal
level. Antithrombin levels are decreased in several
disease states, including hepatic insufficiency, dis-
seminated intravascular coagulation, venous throm-
bosis, and sepsis, and in women who use oral con-
traceptives.
Thromboembolism is rare before the second
decade of life. Although thromboembolism may
occur spontaneously, it usually is associated with pre-
cipitating events, such as surgery, trauma, or preg-
nancy. Heparin therapy remains the mainstay of
management for patients with antithrombin defi-
ciency and acute thrombosis. Although the optimal
level of antithrombin for the treatment of thrombo-
sis is unknown, it is recommended that the
antithrombin concentration be adjusted to more
than 80% of normal activity during the management
of the thrombotic event with heparin and before
surgery in a patient with an acquired or congenital
antithrombin deficiency. The management of
antithrombin deficiency includes infusions of fresh
frozen plasma or antithrombin concentrate. The
concentrates are preferred. Long-term warfarin ther-
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Table II. Congenital coagulation disorders
Disorders
Antithrombin deficiency*
Protein C deficiency*
Protein S deficiency*
Activated protein C resistance*
Prothrombin 20210A*
Heparin cofactor II deficiency *
Homocystinemia*
Dysfibrinogenemia
Increased factor VIII
Abnormal plasminogen
Decreased plasminogen activator
Increased plasminogen activator inhibitor
*The more prevalent congential hypercoagulable disorders.
apy is recommended for patients with antithrombin
deficiencies who have had thrombotic events. The
patients with antithrombin deficiencies should
undergo heparin therapy during pregnancy. The
patients from families with antithrombin deficiencies
should be studied and, if they have antithrombin
deficiencies, should be protected with heparin or
warfarin therapy during times of increased risk (ie,
surgery, trauma, pregnancy, sepsis).
PROTEIN C AND PROTEIN S 
DEFICIENCIES
Protein C and protein S are vitamin K–depen-
dent proteins that are synthesized in the liver. Their
plasma levels may be decreased in patients with
hepatic insufficiency, chronic renal failure, vitamin K
deficiency, and disseminated intravascular coagula-
tion, in patients who undergo major operative pro-
cedures, and during times of active thrombosis.
Protein C, when activated by thrombin, becomes
a major anticoagulant and significantly enhances fi-
brinolytic activity. The activation of protein C is
enhanced 20,000-fold when thrombin is bound to
thrombomodulin on the endothelial cell surface.
Activated protein C degrades activated forms of fac-
tor V (Va) and factor VIII (VIIIa). Protein C also
decreases tissue plasminogen activator inhibitor
activity, thus increasing fibrinolytic potential by
reducing the inhibition of the conversion of plas-
minogen to plasmin. Protein S has no anticoagulant
or fibrinolytic potential on its own but serves as a
cofactor for protein C and enhances the expression
of the anticoagulant effect of protein C.
Congenital protein C deficiency is transmitted as
an autosomal dominant trait, with a prevalence from
1 in 200 to 1 in 300. The incidence rates of throm-
botic events in patients who are heterozygous range
from 0% to 50%.32,33 Patients who are homozygous
often die in early life from thrombotic complications.
Congenital protein C deficiencies are responsible for
2% to 5% of venous thromboses. Protein C is often
30% to 70% of the normal level in patients who are
heterozygous and 5%, or less, in patients who are
homozygous. The patients with protein C deficien-
cies have venous thromboses at an early age, espe-
cially in the lower extremity, cerebral, mesenteric,
and renal veins. Arterial thrombosis is rare. Protein C
and protein S deficiencies have been found in 15% to
20% of the patients with peripheral vascular disease
who are younger than 50 years of age.34
The management of protein C deficiency includes
prophylaxis with heparin or warfarin therapy during
times of risk (ie, surgery, trauma, pregnancy). Fresh
frozen plasma infusions can restore functional levels
of protein C. Life-long anticoagulation therapy with
warfarin is recommended for patients with protein C
deficiencies who have had idiopathic, recurrent, or
life-threatening thromboses.
Cutaneous necrosis is more likely to occur when
warfarin anticoagulation therapy is offered to
patients with protein C deficiencies. Consequently,
all patients, especially those with protein C deficien-
cies, should undergo heparin therapy during the first
3 to 4 days of warfarin therapy, because protein C is
decreased more rapidly than are coagulation factors
II, IX, and X.
The histories of patients with congenital protein
S deficiencies are similar to those histories of patients
with deficiencies of protein C. Protein S has been
identified as responsible for venous thromboses and,
rarely, arterial thrombosis. However, recent data
suggest that many of the patients with protein S
deficiency also have APC-R, which may have been
the major factor that led to the thromboses.
Protein S circulates either as a free protein (30%
to 40%) or bound to the complement pathway pro-
tein, C4b-binding protein. C4b is an acute phase
reactant and is increased during times of acute infla-
mation, which leads to a decrease in free protein S
and thus contributes to the increased tendency
toward thrombosis during inflammatory condi-
tions.35 The management of protein S deficiency is
similar to that of protein C deficiency.
Patients who are homozygous for protein C and
S may have extensive cutaneous necrosis develop as
newborns (purpura fulminans).
ACTIVATED PROTEIN C RESISTANCE
APC-R, the most common risk factor for venous
thrombosis, was initially described by Dahlbäck et
al36 in 1993 and accounts for 52% to 64% of the
inherited causes of thromboses.37 The prevalence of
APC-R in the general population of white origin
ranges from 3% to 15%.38-40 However, it is relative-
ly uncommon in populations of other origins. Many
patients previously diagnosed with functional
antithrombin and protein C and S deficiencies have
been found to have APC-R.
APC-R is characterized by a poor anticoagulant
response to activated protein C. When protein C is
activated, it degrades the activated clotting factors V
and VIII. A molecular defect in factor V occurs
when arginine 506 is replaced with glutamine, ren-
dering Va resistant to degradation by activated pro-
tein C. The altered factor V (factor V Leiden) retains
its procoagulant activity, thus favoring thrombosis.
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Patients with the heterozygous form of APC-R
have as much as a seven-fold increased risk of venous
thrombosis. Those who are homozygous have an
increased risk of approximately 80 fold, and most
will have at least one episode of thrombosis during
their lifetime.38,41 There is increasing evidence that
APC-R is associated with arterial thrombosis, espe-
cially myocardial infarction. The risk for thrombosis
is increased during pregnancy, surgery, and trauma,
with the use of oral contraceptives, and in other sit-
uations that increase the risk for thrombosis.
Patients with APC-R in high thrombotic risk situa-
tions should undergo thrombosis prophylaxis thera-
py, and those patients with recurrent or life-threat-
ening thrombotic events should undergo life-long
anticoagulation therapy with warfarin.
HOMOCYSTINEMIA
Homocysteine, a sulphur-containing amino acid
formed during the metabolism of methionine, is
metabolized with remethylation to methionine or
with transsulfuration to cysteine. Elevated homocys-
teine levels may result from inherited disorders that
alter enzyme activity in the transsulfuration and
methylation pathways. In addition, acquired hyper-
homocystinemia may occur in patients with deficien-
cies of vitamins B12 or B6 or folate. It was first sug-
gested in 1969 that hyperhomocystinemia was asso-
ciated with arterial thrombosis and atherosclerosis.42
It is now well established that hyperhomocystinemia
is a definite risk factor for atherosclerosis,
atherothrombosis, and recurrent venous thrombosis.
Although severe hyperhomocystinemia is rare,
mild homocystinemia occurs in approximately 5% to
7% of the population.43 Homocystinemia may be
detected with the measurement of fasting plasma
homocysteine or after a standardized methionine-
loading test (100 mg/kg). Hyperhomocystinemia is
present if the homocysteine concentration after
methionine loading is increased to more than two
standard deviations above the mean. In addition to the
patient with vitamin deficiencies, hyperhomocystin-
emia has been found in patients with histories of renal
failure, hypothyroidism, pernicious anemia, breast and
pancreas carcinoma, and cigarette smoking.
Hyperhomocystinemia has been shown to cause
endothelial disruption and dysfunction, platelet
activation, and thrombus formation. When homo-
cysteine is oxidized, potent oxygen radicals (espe-
cially hydrogen peroxide, hydroxyl radical, and
superoxide radical) are formed. These superoxide
radicals induce endothelial damage, smooth muscle
proliferation, and activation of platelets and leuko-
cytes. Hyperhomocystinemia alters the normal anti-
thrombotic activity of the endothelium by enhancing
the activity of factors VII and V and decreasing the
activation of protein C by altering  the expression of
thrombomodulin. Hyperhomocystinemia-damaged
endothelium has reduced nitric oxide production.
Homocysteine inhibits the antithrombin binding
activity of the endothelial heparan sulfate and indi-
rectly stimulates platelet aggregation. Homocysteine
interferes with the binding of tissue plasminogen
activator. These toxic effects of hyperhomocystine-
mia contribute to the development of atherosclerot-
ic plaques, arterial atherothrombosis (especially cere-
bral, coronary, and peripheral) events, and idiopathic
venous thromboses.44,45
It is clear that elevated plasma homocysteine con-
centration is a risk factor for atherosclerosis and arte-
rial and venous thrombosis. Patients with premature
atherosclerosis, or unexplained atherothrombosis, or
venous thrombosis should undergo testing for hyper-
homocystinemia. Patients with high homocysteine
levels should undergo treatment with folate (1 to 5
mg/day, as much as 15 mg/day in patients with renal
failure) or B12 or B6. The normalization of the homo-
cysteine level usually occurs within 4 to 6 weeks.44
The normalization has returned platelet and endothe-
lial cell function toward a normal level. Studies of clin-
ical outcomes after normalization of homocysteine are
in progress.
PROTHROMBIN GENE VARIANT (20210A)
In 1996, Poort et al46 examined the prothrom-
bin gene in patients with documented family histo-
ries of venous thrombophilia. A nucleotide change
(a G to A transition) was detected at position 20210
in 18% of the patients.46 In “…a population based
control study, the 20201A allele was identified as a
common allele…” in 1.2% who had a three-fold
increased risk of venous thrombosis.46 Although the
patients with the 20201A allele are at risk for venous
thrombosis, the mechanism for the increased risk is
unclear, except that the patients have elevated levels
of prothrombin (an identified risk factor for throm-
bosis). There are few reports of the homologous
20210AA genotype. The expected prevalence rate is
0.014%.46
Initial reports suggested that the prothrombin
20210G/A genotype was not related to arterial
thrombotic disorders.47 Subsequent reports have
indicated that the allele has a high prevalence rate
(5.7%) in selected patients with arterial throm-
boses.48,49 Patients with the 20210 allele have had
increased frequency of cerebral and coronary throm-
JOURNAL OF VASCULAR SURGERY
402 Silver and Vouyouka February 2000
boses. It has been suggested that the prothrombin
20210A allele and the factor V Leiden mutation will
be found in 63% of families with thrombophilia.50
The management of the prothrombin gene varia-
tion has not been clearly defined, but is likely to require
long-term anticoagulation therapy with warfarin for
those patients with early or recurrent thromboses.
HEPARIN COFACTOR II DEFICIENCY
Heparin cofactor II is produced by the liver and
is a specific inhibitor of thrombin. Heparin cofactor
II deficiency is a rare condition that is transmitted as
an autosomal dominant. It inactivates thrombin by
binding to it in a 1:1 relationship. Heparin enhances
the rate of thrombin inactivation by heparin cofactor
II. Patients with heparin cofactor II deficiencies are
at risk for thrombosis when the cofactor level
becomes 50% or less than normal.51 Heparin cofac-
tor II deficiencies have been reported, in a few
patients, as a risk factor for venous, and fewer arte-
rial, thromboses.
DEFICIENT PLASMINOGEN AND PLAS-
MINOGEN ACTIVATOR ACTIVITY
Increased thrombotic tendencies have been
reported in patients with structural defects in plas-
minogen or defects in the plasminogen activator sys-
tem. Twelve variant forms of the plasminogen mol-
ecule have been described.52 These variants have
functional abnormalities, including altered active
sites and the inability to form activator complexes. A
few patients with recurrent thromboembolism have
been identified as having decreased production of
endothelial-derived plasminogen activator. Patients
with these deficiencies of fibrinolysis may have arte-
rial and venous thromboses and undergo treatment
with long-term warfarin therapy.
CLINICAL IMPLICATIONS
Most of the disorders of hypercoagulability con-
tribute to venous thromboembolism. Of the patients
with heterozygous protein factor deficiency, 60% to
80% will have venous thromboembolism develop by
the ages of 40 to 45 years and 50% will have recur-
rent thromboembolism.53 All patients with juvenile,
idiopathic, or idiopathic recurrent venous thrombo-
sis and a family history of venous thrombosis should
undergo testing for hypercoagulability. Venous
thromboses in unusual sites (eg, mesenteric, portal,
hepatic, cerebral, retinal, and so forth) are often
associated with hypercoagulable disorders.54,55
A hypercoagulable disorder should also be sus-
pected in patients with juvenile, idiopathic, recur-
rent, or multi-level arterial thromboses (eg, 15% to
70% of young patients with arterial occlusive disease
may have a hypercoagulable syndrome).56,57 Arterial
reconstructions have increased rates of failure in
patients with hypercoagulable syndrome, with a six-
fold increase in the need for a second procedure
within 1 year after primary reconstruction in patients
who are hypercoagulable.56,58 The antiphospholipid
syndrome has been detected in 36% of patients with
failed vascular procedures.12,57,59 Twenty-one per-
cent of patients with vascular surgical reconstruc-
tions had heparin-associated antiplatelet antibodies
develop and had a 2.6-fold increase in graft failures.8
Patients with infrainguinal grafts and APC-R had
patency rates of 48% and 33% at 1 and 3 years, and
the “routine” vascular patients had 88% and 71%
patency rates, respectively.60,61 Patients with hyper-
coagulability and infrainguinal vascular reconstruc-
tion have an alarming frequency (20% to 27%) of
acute thrombosis within the first 30 days of recon-
struction when compared with healthy individuals
(1.6% to 2%).34,60 These adverse thrombotic events
are reduced in patients who undergo treatment with
heparin, provided that their hypercoagulable syn-
drome is not caused by heparin. Long-term warfarin
and aspirin therapy substantially reduce the overall
failure rates.34,57,58,61
WHEN TO TEST
The patient with a suspected hypercoagulable dis-
order can undergo testing during the episode of
thrombosis for heparin-associated antiplatelet antibod-
ies, anticardiolipin antibodies, homocysteine, the
Leiden mutation, and the prothrombin variant. The
other factors may be consumed during the clotting
process or reduced by the administration of warfarin,
liver failure, or sepsis. The authors treat suspected
hypercoagulable disorders with warfarin therapy for 6
months or more, until the patient have not had a
thrombosis for 2 or more months. The warfarin ther-
apy is then discontinued, and the patient undergoes
treatment with heparin (usually low–molecular weight
heparin) for 2 weeks. When the heparin therapy is dis-
continued, and 2 to 3 days later, blood is obtained for
hypercoagulable studies. Heparin therapy is immedi-
ately restarted and warfarin therapy is begun while the
physicians await the results of the studies.
If a patient is found to have one of the hyperco-
agulable conditions, the family of the patients
should also undergo testing. In our experience,
heparin-associated antiplatelet antibodies, the lupus
anticoagulant, and homocystinemia are the more
common causes of reconstructive arterial failures.
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SUMMARY
The recognition of acquired or congenital hyper-
coagulable disorders has major implications for the
patient and the family. Congenital and acquired hyper-
coagulable defects are associated with increased risk of
arterial and venous thrombosis and arterial reconstruc-
tive failures.
Greek mythology notes that Athena saved the
blood from Medusa’s body and gave it to Aesculapius.
The blood from the left side of her body was a fatal
poison, and the blood from the right side of her body
had the power to revive the dead. It is hoped that a
better understanding of the hypercoagulable disor-
ders, although it would not cause patients to arise
from their deathbeds, will reduce the morbidity and
mortality.
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